Protagonist Therapeutics (PTGX) Return on Capital Employed (2016 - 2026)
Protagonist Therapeutics (PTGX) reported Return on Capital Employed of 21.98% for Q1 2026, down 2582.0% on a YoY basis from 0.89% in Q1 2025, and up 11.12% sequentially from 24.73% in Q4 2025.
Protagonist Therapeutics (PTGX) Return on Capital Employed (2016 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 11 years of Return on Capital Employed data on file, last reported at 21.98% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed fell 2582.0% year-over-year to 21.98%; the trailing twelve-month figure through Mar 2026 stood at 21.98% (down 2582.0% YoY), and the FY2025 full-year result was 23.92%, down 7410.0% from the prior year.
- Return on Capital Employed grew to 21.98% in Q1 2026, from 24.73% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 40.33% in Q4 2024 to a low of 66.29% in Q1 2023.
- A 5-year average of 18.18% and a median of 24.73% in 2025 frame the typical range for Return on Capital Employed.
- Across the five-year window, Return on Capital Employed surged 9906 bps in 2024 and plunged 6506 bps in 2025, its largest moves.
- Tracing PTGX's Return on Capital Employed over 5 years: stood at 56.17% in 2022, then jumped by 48 bps to 29.02% in 2023, then soared by 239 bps to 40.33% in 2024, then sank by 161 bps to 24.73% in 2025, then climbed by 11 bps to 21.98% in 2026.
- Business Quant data shows PTGX's Return on Capital Employed at 21.98% in Q1 2026, 24.73% in Q4 2025, and 2.86% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 10.46% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -68.47% |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -68.84% |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -21.98% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.98% |
| Dec 31, 2025 | -24.73% |
| Sep 30, 2025 | 2.86% |
| Jun 30, 2025 | 3.45% |
| Mar 31, 2025 | 3.84% |
| Dec 31, 2024 | 40.33% |
| Sep 30, 2024 | 26.41% |
| Jun 30, 2024 | 26.23% |
| Mar 31, 2024 | 32.77% |
| Dec 31, 2023 | -29.02% |
| Sep 30, 2023 | -51.52% |
| Jun 30, 2023 | -58.00% |
| Mar 31, 2023 | -66.29% |
| Dec 31, 2022 | -56.17% |
| Sep 30, 2022 | -50.80% |
| Jun 30, 2022 | -46.14% |
| Mar 31, 2022 | -40.37% |
| Dec 31, 2021 | -39.77% |
| Sep 30, 2021 | -30.80% |
| Jun 30, 2021 | -26.45% |